Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Keytruda
Biotech
PDS reports 39 months OS in phase 2 head and neck cancer trial
PDS has reported final phase 2 data, linking a combination of its immunotherapy and Keytruda to median overall survival of 39.3 months.
Nick Paul Taylor
Aug 25, 2025 9:00am
Fierce Pharma
Roche touts Tecentriq biomarker win in bladder cancer
Aug 18, 2025 4:17pm
Cancer vaccine's 'narrow' fail won't stop IO heading to FDA
Aug 11, 2025 9:48am
Fierce Pharma
Merck unveils $3B cost-cutting plan
Jul 29, 2025 8:15am
Merus hails 'unprecedented' survival on solid tumor bispecific
May 23, 2025 7:35am
Immutep's LAG-3 agent posts 'impressive' survival data
May 5, 2025 10:37am
